Joint Pain Injections Market Trends, Share, Growth Factors, Analysis, and Forecast 2025-2033

Market Overview

The global Joint Pain Injections Market reached a size of USD 6.0 Billion in 2024. It is projected to grow at a CAGR of 7.03% during the forecast period from 2025 to 2033, reaching a market value of USD 11.5 Billion by 2033. Market growth is driven by factors such as the aging population, increased prevalence of osteoarthritis and rheumatoid arthritis, advancements in medical technology, and heightened awareness accelerated by the COVID-19 pandemic.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Years: 2025-2033

Joint Pain Injections Market Key Takeaways

• Current Market Size: USD 6.0 Billion in 2024
• CAGR: 7.03% (2025-2033)
• Forecast Period: 2025-2033
• The market is driven by a growing geriatric population with increased osteoarthritis and rheumatoid arthritis cases.
• Increasing preference for minimally invasive outpatient procedures fosters market expansion.
• Technological advancements such as longer lasting injectables and targeted drug delivery systems enhance treatment efficacy.
• Key regional markets include North America, Europe, and a fast-growing Asia-Pacific region.
• Strategic collaborations and regulatory approvals are pivotal factors for market competition.
• Growing awareness due to improved insurance coverage and promotion by pharmaceutical companies also contributes to growth.

Sample Request Link: https://www.imarcgroup.com/joint-pain-injections-market/requestsample

Market Growth Factors

The expansive aging population worldwide is a primary driver for the joint pain injections market. Elderly individuals face higher risks of joint pain and degenerative diseases such as osteoarthritis. This demographic shift generates increased demand for effective pain management solutions like joint pain injections, aiming to enhance mobility and quality of life. Pharmaceutical companies and healthcare providers have been investing in R&D and marketing to cater to this expanding and receptive market segment.

Sports-related injuries significantly contribute to market growth. Athletes and physically active individuals often sustain ligament tears and cartilage damage leading to chronic joint pain. The preference for minimally invasive treatments such as corticosteroid and hyaluronic acid injections stems from their efficacy and faster recovery compared to traditional surgery. This trend bolsters demand for joint pain injections across diverse populations beyond athletes.

The rising prevalence of chronic joint conditions such as osteoarthritis and rheumatoid arthritis also fuels market expansion. Osteoarthritis affects millions globally by causing cartilage degradation, resulting in pain and limited joint function. Rheumatoid arthritis, an autoimmune disease, causes joint inflammation and stiffness. Joint pain injections provide effective pain relief and improved function, making them attractive therapeutic options. Consequently, the growing patient base drives sustained market growth.

Market Segmentation

By Type of Injection:

• Steroid Joint Injections: Popular for rapid anti-inflammatory effects providing quick pain relief in conditions like arthritis and tendonitis.
• Hyaluronic Acid Injections: Largest segment, favored for biocompatibility and natural lubricating properties, especially in osteoarthritis patients.
• Platelet-rich Plasma (PRP) Injections: Growing interest due to regenerative medicine potential, using patient's own blood to promote healing.
• Placental Tissue Matrix (PTM) Injections: Emerging biologics segment, rich in growth factors aiding tissue regeneration and reducing inflammation.
• Others: Includes new therapies and novel drug formulations addressing limitations of existing treatments.

By Joint Type:

• Knee and Ankle: Largest segment driven by sports injuries and degenerative conditions; benefits from advanced imaging and minimally invasive procedures.
• Hip Joint: Growth fueled by arthritis, osteoporosis prevalence, and innovations in longer-lasting pain relief injections.
• Shoulder and Elbow: Driven by repetitive stress injuries, rotator cuff ailments, and increased preference for non-surgical interventions.
• Facet Joints of the Spine: Impacted by rising spinal disorders and improved image-guided injection techniques enhancing targeted pain management.
• Others: Includes wrists, fingers, and small joints, growth tied to rheumatoid arthritis prevalence and aging population.

By Distribution Channel:

• Hospital Pharmacies: Largest market share due to the demand for specialized care and immediate pain relief in controlled hospital environments.
• Drug Stores and Retail Pharmacies: Increased accessibility and convenience make these vital distribution points, including OTC and prescription injections.
• Online Providers: Rapid growth fueled by e-commerce, telehealth services, and the pandemic accelerating home delivery and digital literacy.

By Region:

• North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Regional Insights

North America leads the joint pain injections market, holding the largest market share as of 2024. This dominance stems from a high prevalence of chronic joint conditions among its aging population, advanced healthcare infrastructure, substantial healthcare expenditure, and broad awareness of treatment options. The presence of leading pharmaceutical companies and a strong focus on research and development further contribute to robust market growth in this region.

Recent Developments & News

• December 2023: Bioventus Inc. finalized a national agreement with Aetna™ Medicare Advantage plans to provide DUROLANE, a hyaluronic acid-based treatment for knee osteoarthritis pain, to over 3 million Medicare Advantage enrollees.
• December 2021: Avanos Medical, Inc. acquired OrthogenRx, Inc., a company specializing in viscosupplementation treatments for knee osteoarthritis pain.
• March 2023: The US FDA approved sarilumab (Kevzara), developed by Sanofi and Regeneron, as the first biologic treatment for polymyalgia rheumatica in adults.

Key Players

• Anika Therapeutics Inc.
• Bioventus LLC
• OrthogenRx Inc. (Avanos Medical Inc.)
• Sanofi
• Zimmer Biomet Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

👉Get Custom Market Research for Your Business👈

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302